Beta-blockers and cancer: An emerging treatment

Shahid Akbar, John R Richards

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The nexus of stress, the sympathetic nervous system, and cancer has been established. A new potential benefit for the use of β-blockers as anti-cancer drugs has emerged in the past decade. The results of several retrospective studies suggest that use of β-blockers before the diagnosis of cancer could have preventive and protective effects against certain types of cancer, such as non-small cell lung carcinoma, melanoma, breast, pancreatic, and prostate cancers. Experimental and clinical observations are still inconclusive with some inconsistent findings. As the results of more studies become available, indicators are favorable for a positive role of some β-blockers against certain forms of cancers.

Original languageEnglish (US)
Title of host publicationBeta-Blockers
Subtitle of host publicationPhysiological, Pharmacological and Therapeutic Implications
PublisherNova Science Publishers, Inc.
Pages231-262
Number of pages32
ISBN (Electronic)9781536133127
ISBN (Print)9781536133110
StatePublished - Jan 1 2018

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Beta-blockers and cancer: An emerging treatment'. Together they form a unique fingerprint.

  • Cite this

    Akbar, S., & Richards, J. R. (2018). Beta-blockers and cancer: An emerging treatment. In Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications (pp. 231-262). Nova Science Publishers, Inc..